AMBFF logo

Ambu A/S (AMBFF) Análisis de Acciones

Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Ambu A/S (AMBFF) opera en el sector Healthcare, cotizado por última vez a $ con una capitalización de mercado de 0. Calificado con 48/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.

Ultimo analisis: 16 mar 2026
Puntuación de IA de 48/100

Ambu A/S (AMBFF) Resumen de Asistencia Médica y Tuberías

CEOBritt Meelby Jensen
Empleados5000
Sede CentralBallerup, DK
Año de la oferta pública inicial (OPI)2017

Ambu A/S is a medical device company focused on single-use endoscopes and related products, serving hospitals, clinics, and rescue services globally. With a focus on innovation in visualization, anesthesia, and patient monitoring, Ambu aims to improve patient outcomes and streamline healthcare workflows, holding a significant position in the disposable endoscope market.

Procedencia de los datos | Datos financieros Análisis cuantitativo NASDAQ Análisis: 16 mar 2026

Tesis de Inversión

Ambu A/S presents a notable research candidate due to its focus on single-use endoscopes, a market poised for growth driven by increasing awareness of infection control and workflow efficiency. With a market capitalization of $3.66 billion and a profit margin of 8.9%, Ambu demonstrates financial stability. Key growth catalysts include expanding its product portfolio and increasing market penetration in North America and Europe. However, potential risks include competition from established medical device companies and the need to maintain a high level of innovation to stay ahead of the curve. The company's beta of 1.40 suggests higher volatility compared to the market.

Basado en las finanzas de FMP y el análisis cuantitativo

Puntos clave

  • Market capitalization of $3.66 billion indicates a substantial company size within the medical device industry.
  • P/E ratio of 35.45 suggests investors are willing to pay a premium for Ambu's earnings, reflecting growth expectations.
  • Gross margin of 55.9% demonstrates strong pricing power and efficient cost management.
  • Dividend yield of 0.57% provides a small income stream for investors.
  • Beta of 1.40 indicates the stock is more volatile than the market, potentially offering higher returns but also greater risk.

Competidores y Pares

Fortalezas

  • Focus on single-use endoscopes addresses infection control concerns.
  • Innovative product portfolio with continuous R&D efforts.
  • Global presence and established distribution network.
  • Strong brand reputation in the medical device industry.

Debilidades

  • Reliance on single-use products may limit market reach.
  • Higher price point compared to reusable endoscopes.
  • Exposure to regulatory changes and healthcare policies.
  • Dependence on key suppliers for raw materials and components.

Catalizadores

  • Ongoing: Expansion of single-use endoscope product line to address new medical procedures.
  • Upcoming: Regulatory approvals for new medical devices in key markets (e.g., FDA approval in the U.S.).
  • Ongoing: Increasing adoption of single-use endoscopes in hospitals and clinics worldwide.
  • Upcoming: Strategic partnerships with healthcare providers and distributors to expand market reach.
  • Ongoing: Growing awareness of infection control and the benefits of single-use devices.

Riesgos

  • Potential: Competition from established medical device companies with greater resources.
  • Ongoing: Regulatory changes and healthcare policies may impact product approvals and reimbursement rates.
  • Potential: Economic downturns may reduce healthcare spending and demand for medical devices.
  • Ongoing: Product recalls or safety concerns could damage reputation and lead to liability claims.
  • Potential: Intellectual property infringement or patent disputes.

Oportunidades de crecimiento

  • Expansion in the U.S. Market: Ambu has a significant opportunity to expand its presence in the U.S. market, driven by the increasing adoption of single-use endoscopes. The U.S. endoscopy market is estimated to be worth billions of dollars, and Ambu's innovative products and strong sales force can help it capture a larger share. Timeline: Ongoing, with continuous efforts to increase market penetration.
  • Product Innovation and Development: Ambu can drive growth by continuing to innovate and develop new products in the fields of visualization, anesthesia, and patient monitoring. The company's R&D efforts should focus on addressing unmet clinical needs and improving patient outcomes. Timeline: Ongoing, with new product launches planned regularly.
  • Strategic Partnerships and Acquisitions: Ambu can accelerate its growth by forming strategic partnerships and acquiring complementary businesses. This can help the company expand its product portfolio, enter new markets, and gain access to new technologies. Timeline: Opportunistic, with potential deals evaluated on an ongoing basis.
  • Penetration of Emerging Markets: Ambu has the opportunity to expand its presence in emerging markets such as China and India, where healthcare spending is growing rapidly. These markets offer significant growth potential for Ambu's products and services. Timeline: Long-term, with gradual expansion efforts over the next 5-10 years.
  • Increase in Single-Use Endoscope Adoption: The increasing awareness of infection control and the benefits of single-use endoscopes are driving adoption in hospitals and clinics worldwide. Ambu can capitalize on this trend by educating healthcare providers about the advantages of its products and expanding its sales and marketing efforts. Timeline: Ongoing, with continuous efforts to promote the benefits of single-use endoscopes.

Oportunidades

  • Expanding into new geographic markets and healthcare segments.
  • Developing new applications for single-use endoscopes.
  • Forming strategic partnerships and acquisitions.
  • Increasing adoption of single-use devices in emerging markets.

Amenazas

  • Competition from established medical device companies.
  • Technological advancements may render existing products obsolete.
  • Economic downturns may reduce healthcare spending.
  • Product recalls or safety concerns could damage reputation.

Ventajas competitivas

  • Proprietary technology in single-use endoscopes.
  • Strong brand reputation for quality and innovation.
  • Established distribution network and customer relationships.
  • Intellectual property protection through patents.

Acerca de AMBFF

Founded in 1937 and headquartered in Ballerup, Denmark, Ambu A/S develops, produces, and sells medical devices and solutions to hospitals, clinics, and rescue services worldwide. The company has evolved from its initial focus on resuscitation equipment to become a key player in single-use endoscopy. Ambu's product portfolio includes a range of endoscopy products such as bronchoscopes and monitors, as well as neurology products like EEG and EMG electrodes. Additionally, the company offers cardiology products, including ECG electrodes, and airway management and anesthesia products, such as video laryngoscopes and resuscitators. Ambu's single-use endoscopes are designed to eliminate the need for sterilization, reducing the risk of cross-contamination and improving workflow efficiency in healthcare settings. The company's global presence allows it to serve a diverse customer base with innovative and cost-effective medical solutions.

Qué hacen

  • Develops single-use endoscopes for various medical procedures.
  • Produces and sells medical devices for visualization, anesthesia, and patient monitoring.
  • Offers neurology products, including EEG and EMG electrodes.
  • Provides cardiology products, such as ECG electrodes.
  • Manufactures airway management and anesthesia products, including video laryngoscopes and resuscitators.
  • Supplies extrication collars, CPR breathing barriers, and training manikins.

Modelo de Negocio

  • Develops and manufactures medical devices in-house.
  • Sells products directly to hospitals, clinics, and rescue services.
  • Generates revenue through product sales and distribution agreements.
  • Invests in research and development to create innovative medical solutions.

Contexto de la Industria

Ambu A/S operates in the medical device industry, which is characterized by continuous innovation and stringent regulatory requirements. The global medical device market is expected to grow, driven by factors such as an aging population, increasing prevalence of chronic diseases, and technological advancements. Ambu's focus on single-use endoscopes positions it well to capitalize on the growing demand for infection control and efficient workflow solutions. Competitors include companies like Ambu, Inc. (AMFPF), which also offer medical devices and equipment. The industry is highly competitive, with companies constantly striving to develop new and improved products.

Clientes Clave

  • Hospitals and clinics
  • Emergency medical services (EMS)
  • Rescue services
  • Healthcare providers
Confianza de la IA: 81% Actualizado: 16 mar 2026

Finanzas

Gráfico e información

Precio de la acción de Ambu A/S (AMBFF): Price data unavailable

Últimas noticias

Consenso de analistas

Calificación de Consenso

Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para AMBFF.

Objetivos de Precios

Análisis del precio objetivo de Wall Street para AMBFF.

MoonshotScore

48/100

¿Qué significa esta puntuación?

El MoonshotScore califica el potencial de crecimiento de AMBFF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.

Liderazgo: Britt Meelby Jensen

CEO

Britt Meelby Jensen has served as the CEO of Ambu A/S, managing a workforce of 5,000 employees. Her career spans various leadership roles within the healthcare and pharmaceutical industries. She brings extensive experience in strategic development, commercial operations, and global market expansion. Jensen's background includes a strong focus on driving innovation and improving patient outcomes through advanced medical technologies. Her leadership is characterized by a commitment to sustainable growth and operational excellence.

Historial: Under Britt Meelby Jensen's leadership, Ambu A/S has focused on expanding its single-use endoscopy portfolio and strengthening its global market position. Key achievements include driving revenue growth, enhancing operational efficiency, and fostering a culture of innovation within the company. Jensen has also overseen strategic acquisitions and partnerships to broaden Ambu's product offerings and market reach.

Información del mercado OTC de AMBFF

The OTC Other tier represents the lowest tier of the OTC market, indicating that Ambu A/S (AMBFF) may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited regulatory oversight and reporting requirements compared to those listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier involves higher risks due to the potential for less transparency and liquidity.

  • Nivel OTC: OTC Other
  • Estado de divulgación: Unknown
Liquidez: Liquidity for stocks on the OTC Other tier, such as AMBFF, can be limited. Trading volume may be low, resulting in wider bid-ask spreads and making it more difficult to buy or sell shares quickly without significantly impacting the price. Investors should exercise caution and be aware of the potential for price volatility and illiquidity when trading AMBFF.
Factores de riesgo OTC:
  • Limited financial disclosure increases information asymmetry.
  • Lower trading volume can lead to price volatility.
  • Potential for fraud or manipulation is higher on the OTC Other tier.
  • Lack of regulatory oversight may result in inadequate investor protection.
  • Delisting risk if the company fails to meet minimum requirements.
Lista de verificación de diligencia debida:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team's experience and track record.
  • Check for any regulatory actions or legal proceedings.
  • Monitor trading volume and price volatility.
  • Consult with a financial advisor before investing.
Señales de legitimidad:
  • Established history of operations since 1937.
  • Global presence and distribution network.
  • Focus on innovative medical devices and solutions.
  • Presence in the single-use endoscopy market.
  • CEO with experience in the healthcare industry.

Preguntas Comunes Sobre AMBFF

¿Cuáles son los factores clave para evaluar AMBFF?

Ambu A/S (AMBFF) actualmente tiene una puntuación IA de 48/100, indicando puntuación baja. Fortaleza clave: Focus on single-use endoscopes addresses infection control concerns.. Riesgo principal a monitorear: Potential: Competition from established medical device companies with greater resources.. Esto no es asesoramiento financiero.

¿Qué es el MoonshotScore de AMBFF?

AMBFF actualmente puntúa 48/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.

¿Con qué frecuencia se actualizan los datos de AMBFF?

Los precios de AMBFF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.

¿Qué dicen los analistas sobre AMBFF?

La cobertura de analistas para AMBFF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.

¿Cuáles son los riesgos de invertir en AMBFF?

Las categorías de riesgo para AMBFF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Competition from established medical device companies with greater resources.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.

¿Cuál es la relación P/E de AMBFF?

La relación P/E para AMBFF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.

¿Está AMBFF sobrevalorada o infravalorada?

Determinar si Ambu A/S (AMBFF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.

¿Cuál es el rendimiento por dividendo de AMBFF?

Ambu A/S (AMBFF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.

Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.

Recursos Oficiales

Análisis actualizado el Puntuación de IA actualizada diariamente
Fuentes de Datos y Metodología
Datos de mercado proporcionados por Financial Modeling Prep y Yahoo Finance. Análisis de IA por algoritmos propietarios de Stock Expert AI. Indicadores técnicos mediante cálculos estándar de la industria. Última actualización: .

Datos proporcionados solo con fines informativos.

Notas de análisis
  • OTC stock carries higher risk, do thorough due diligence.
Fuentes de datos

Popular Stocks